Aktie A3EJMZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Creative Medical Technology Holdings, Inc.

Aktien

A3EJMZ

US22529Y4089

CELZ

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:00 10.05.2024 		% 5 Tage % 1. Jan.
4,35 USD +1,16 % Intraday Chart für Creative Medical Technology Holdings, Inc. -1,02 % -5,64 %
22.03. Creative Medical Technology Holdings, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
07.03. Creative Medical Technology Holdings Inc. gibt die FDA-Zulassung für eine Therapie zur Vorbeugung von Typ-1-Diabetes im Rahmen des Expanded Access bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Creative Medical Technology Holdings Provides Corporate Update
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures
Creative Medical Shares Rally Premarket on FDA Orphan Designation
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony
Top Premarket Gainers
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem
Creative Medical Technology Holdings Provides Corporate Update
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem Novel Cell Therapy to Treat Chronic Lower Back Pain
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine using AlloStem for the Treatment of Chronic Lower Back Pain
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3EJMZ Aktie
  4. Nachrichten Creative Medical Technology Holdings, Inc.
  5. Andere Sprachen